Showing 5,701 - 5,720 results of 45,491 for search '(( 50 ((we decrease) OR (a decrease)) ) OR ( 5 ((ng decrease) OR (mean decrease)) ))', query time: 1.01s Refine Results
  1. 5701

    Stride-to-stride fluctuations for the ankle were significantly decreased for the sound leg compared to the prosthetic leg. by Shane R. Wurdeman (582199)

    Published 2014
    “…Through the adaptation, a significant U-shaped quadratic trend was present, with significantly increased stride-to-stride fluctuations at the initial visit and final visit compared to the middle of the adaptation period. (mean ± SEM) SL: sound leg; PL: prosthetic leg; MA: “more appropriate” prosthesis; LA: “less appropriate” prosthesis; V1: initial visit; V2: second visit; V3: final visit. …”
  2. 5702
  3. 5703

    Antagonism of miR-21 reversed EMT phenotype, as well as decreased cell migration and invasion. by Mingli Han (318317)

    Published 2013
    “…<p>MDA-MB-231 cells were transfected with hsa-miR-21 antagomir or hsa-miR-21 antagomir control at a final concentration of 50 nmol for 48 h. (A) MDA-MB-231 cells were treated with hsa-miR-21 antagomir decreased the expression of miR-21, as compared to control groups (n1 = n2 = 3; p = 0.0015), by real-time RT-PCR analysis. …”
  4. 5704
  5. 5705
  6. 5706
  7. 5707
  8. 5708

    Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice by Michael T Buckley (37161)

    Published 2011
    “…Normal non-transgenic mouse bladders weigh approximately 10.0 mg at the same age, and Ha-transgenic mice with superficial bladder cancer have a 3 fold and higher bladder weight. , Male belinostat-treated mice (n = 4, 327.5 mg average weight) showed a two-fold decrease (50%, p = 0.03) in bladder weight versus control (n = 4, 652.5 mg average weight). , Female belinostat-treated mice (n = 5, 34.0 mg average weight) showed a 36% decrease (p = 0.04) in bladder weight versus control (n = 6, 53.3 mg average weight).…”
  9. 5709
  10. 5710
  11. 5711
  12. 5712
  13. 5713
  14. 5714
  15. 5715

    Effects of vidarabine, V2E, V3E and V5E on AC activity in the heart of WT and AC5KO mice. by Kenji Suita (750993)

    Published 2025
    “…<p>(A) Vidarabine (Vida), V2E, V3E and V5E similarly and significantly decreased ISO (50 µmol/L)-stimulated AC activity in the WT heart in a dose-dependent manner. …”
  16. 5716
  17. 5717
  18. 5718
  19. 5719
  20. 5720